We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

By LabMedica International staff writers
Posted on 30 Nov 2021
Print article
Image: Illustration is of the Vertical Auto Profile (VAP) Lipid test with clear demarcation of the different lipoprotein classes and subclasses. (Photo courtesy of VAP Diagnostics Laboratory)
Image: Illustration is of the Vertical Auto Profile (VAP) Lipid test with clear demarcation of the different lipoprotein classes and subclasses. (Photo courtesy of VAP Diagnostics Laboratory)
Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients with diabetes with worsening glycemic control.

Lipoprotein(a) (Lp(a)) is a highly atherogenic lipoprotein that attaches to the apoB 100 moiety of LDL-C particles. Lp(a) is concentration is generally fully expressed by the second year in childhood. Lp(a) is highly heritable, with great concordance between parental levels.

Pediatric Endocrinologists at the University of Alabama School of Medicine (Birmingham, AL, USA) investigate the relationships between serum concentrations of Lp(a) with low-density lipoprotein cholesterol (LDL-C), race, body mass index (BMI), and HbA1c in children with diabetes. Their secondary aim was to evaluate the factors associated with elevated Lp(a) levels. The carried out across-sectional retrospective chart review of pediatric patients, ages 12-19 years, including 607 type 1 diabetes (T1D) and 93 type 2 diabetes (T2D); 49% were male, mean age was 13.2 ± 3.08 years, and the median Lp(a) was 8.00 mg/dL. In addition to standard lipid profile testing, the clinical laboratory also offered Vertical Auto Profile (VAP) testing through a commercial laboratory (Atherotech, Birmingham, AL, USA).

The investigators reported that the Black children had an increased relative risk (RR) of higher Lp(a) compared with White ones (RR 1.25). The median Lp(a) was significantly higher in Black people than in White people, 9 (6-14) versus 7 (5-11). Among patients with T1D, Black people had an increased relative risk of higher Lp(a) than White people (RR 1.23). In T2D, Black participants have 43% higher risk of having elevated Lp(a) than White participants (RR 1.43). In T1D, a 5 mg/dL increase in LDL-C results in 2% increase in Lp(a). In T2D, a 5 mg/dL increase of LDL-C results in an increase of Lp(a) by 3%. LDL-C and BMI are independently associated with Lp(a) (RR = 1.02 and RR = 0.98), respectively. Interestingly, patients with T1D had higher mean levels of Lp(a) despite having a lower BMI compared to children with T2D. Patients with T1D had higher mean HbA1c than those with T2D (9.14% [5.88-12.4] versus 8.27% [5.67-10.87]).

The authors concluded that Lp(a) is strongly associated with LDL-C in children with diabetes, indicating a reduction of LDL-C may additionally reduce cardiovascular risk by lowering Lp(a) levels. Black children with diabetes have a significant burden of Lp(a) concentrations compared with White children. It may be important to consider Lp(a) screening in children with diabetes for disease risk management and implement stricter therapeutic goals for LDL-C reduction. The study was published in the November, 2021 issue of Journal of the Endocrine Society.

Related Links:
University of Alabama School of Medicine

Gold Supplier
Hemostasis Analyzer
STA R Max 3
Electrolyte Analyzer
POC Clinical Chemistry Analyzer
Automatic Biochemistry Analyzer
Falcon 260

Print article
IIR Middle East


Molecular Diagnostics

view channel

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more


view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.